메뉴 건너뛰기




Volumn 6, Issue 1, 2014, Pages 55-67

Patient safety and minimizing risk with insulin administration - Role of insulin degludec

Author keywords

Basal insulin; Diabetes; Hypoglycemia; Safety

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN;

EID: 84899764881     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/DHPS.S59566     Document Type: Review
Times cited : (28)

References (71)
  • 1
    • 84864460325 scopus 로고    scopus 로고
    • Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin
    • Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012; 29(8): 2104-2114.
    • (2012) Pharm Res , vol.29 , Issue.8 , pp. 2104-2114
    • Jonassen, I.1    Havelund, S.2    Hoeg-Jensen, T.3    Steensgaard, D.B.4    Wahlund, P.O.5    Ribel, U.6
  • 2
    • 84859746575 scopus 로고    scopus 로고
    • Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec
    • 42-LB, (abstract)
    • Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes 2011; 60 Suppl 1A: 42-LB (abstract).
    • (2011) Diabetes , vol.60 , Issue.SUPPL. 1A
    • Kurtzhals, P.1    Heise, T.2    Strauss, H.M.3
  • 3
    • 34948861041 scopus 로고    scopus 로고
    • Refining basal insulin therapy: What have we learned in the age of analogues?
    • Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev. 2007; 23(6): 441-454.
    • (2007) Diabetes Metab Res Rev , vol.23 , Issue.6 , pp. 441-454
    • Devries, J.H.1    Nattrass, M.2    Pieber, T.R.3
  • 4
    • 34547908855 scopus 로고    scopus 로고
    • Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies
    • Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007; 9(5): 648-659.
    • (2007) Diabetes Obes Metab , vol.9 , Issue.5 , pp. 648-659
    • Heise, T.1    Pieber, T.R.2
  • 5
    • 84883510524 scopus 로고    scopus 로고
    • β-Cell differentiation and regeneration in type 1 diabetes
    • Ding L, Gysemans C, Mathieu C. β-Cell differentiation and regeneration in type 1 diabetes. Diabetes Obes Metab. 2013; 15 Suppl 3: 98-104.
    • (2013) Diabetes Obes Metab , vol.15 , Issue.SUPPL. 3 , pp. 98-104
    • Ding, L.1    Gysemans, C.2    Mathieu, C.3
  • 6
    • 0013913701 scopus 로고
    • Application of newer concepts in diabetes
    • Fineberg SK. Application of newer concepts in diabetes. J Am Geriatr Soc. 1966; 14(5): 463-471.
    • (1966) J Am Geriatr Soc , vol.14 , Issue.5 , pp. 463-471
    • Fineberg, S.K.1
  • 7
    • 84899758364 scopus 로고    scopus 로고
    • Accessed January 26, National Diabetes Information Clearinghouse (NDIC), 2008, NIH Publication No 09-3873. Bethesda, MD: NDIC; Available from
    • National Diabetes Information Clearinghouse (NDIC). Diabetes overview [web page on the Internet]. NIH Publication No 09-3873. Bethesda, MD: NDIC; 2008. Available from: http://diabetes. niddk. nih. gov/dm/pubs/overview/. Accessed January 26, 2014.
    • (2014) Diabetes overview [web page on the Internet]
  • 8
    • 84871995815 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2013
    • American Diabetes Association
    • American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013; 36 Suppl 1: S11-S66.
    • (2013) Diabetes Care , vol.36 , Issue.SUPPL. 1
  • 9
    • 0023916553 scopus 로고
    • Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
    • Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988; 318(19): 1231-1239.
    • (1988) N Engl J Med , vol.318 , Issue.19 , pp. 1231-1239
    • Polonsky, K.S.1    Given, B.D.2    Hirsch, L.J.3
  • 10
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD)
    • Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6): 1364-1379.
    • (2012) Diabetes Care , vol.35 , Issue.6 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 11
    • 70350328268 scopus 로고    scopus 로고
    • Restaging insulin therapy for patients with type 2 diabetes
    • Garber AJ. Restaging insulin therapy for patients with type 2 diabetes. Diabetes Obes Metab. 2009; 11 Suppl 5: 1-5.
    • (2009) Diabetes Obes Metab , vol.11 , Issue.SUPPL. 5 , pp. 1-5
    • Garber, A.J.1
  • 12
    • 2542576404 scopus 로고    scopus 로고
    • Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes
    • Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53(6): 1614-1620.
    • (2004) Diabetes , vol.53 , Issue.6 , pp. 1614-1620
    • Heise, T.1    Nosek, L.2    Rønn, B.B.3
  • 13
    • 80054071230 scopus 로고    scopus 로고
    • The future of basal insulin supplementation
    • Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes Technol Ther. 2011; 13 Suppl 1: S103-S108.
    • (2011) Diabetes Technol Ther , vol.13 , Issue.SUPPL. 1
    • Simon, A.C.1    DeVries, J.H.2
  • 14
    • 84859842346 scopus 로고    scopus 로고
    • Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study
    • Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012; 29(5): 682-689.
    • (2012) Diabet Med , vol.29 , Issue.5 , pp. 682-689
    • Peyrot, M.1    Barnett, A.H.2    Meneghini, L.F.3    Schumm-Draeger, P.M.4
  • 15
    • 0017127682 scopus 로고
    • The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man
    • Garber AJ, Cryer PE, Santiago JV, Haymond MW, Pagliara AS, Kipnis DM. The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest. 1976; 58(1): 7-15.
    • (1976) J Clin Invest , vol.58 , Issue.1 , pp. 7-15
    • Garber, A.J.1    Cryer, P.E.2    Santiago, J.V.3    Haymond, M.W.4    Pagliara, A.S.5    Kipnis, D.M.6
  • 17
    • 0036020278 scopus 로고    scopus 로고
    • Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II diabetes
    • Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002; 45(7): 937-948.
    • (2002) Diabetologia , vol.45 , Issue.7 , pp. 937-948
    • Cryer, P.E.1
  • 18
    • 0036314189 scopus 로고    scopus 로고
    • Hypoglycemia-associated autonomic failure in advanced type 2 diabetes
    • Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002; 51(3): 724-733.
    • (2002) Diabetes , vol.51 , Issue.3 , pp. 724-733
    • Segel, S.A.1    Paramore, D.S.2    Cryer, P.E.3
  • 20
    • 0001909792 scopus 로고    scopus 로고
    • Impaired hypoglycaemia awareness
    • In: Frier BM, Fisher M, editors., Chichester: Wiley
    • Frier BM, Fisher M. Impaired hypoglycaemia awareness. In: Frier BM, Fisher M, editors. Hypoglycaemia in Clinical Diabetes. Chichester: Wiley; 1999: 111-146.
    • (1999) Hypoglycaemia in Clinical Diabetes , pp. 111-146
    • Frier, B.M.1    Fisher, M.2
  • 21
    • 84881416448 scopus 로고    scopus 로고
    • Severe hypoglycaemia and cardiovascular disease: Systematic review and meta-analysis with bias analysis
    • Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013; 347: f4533.
    • (2013) BMJ , vol.347
    • Goto, A.1    Arah, O.A.2    Goto, M.3    Terauchi, Y.4    Noda, M.5
  • 22
    • 33748366186 scopus 로고    scopus 로고
    • Hypoglycemia in type 1 and type 2 diabetes: Physiology, pathophysiology, and management
    • Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: physiology, pathophysiology, and management. Clin Diabetes. 2006; 24(3): 115-121.
    • (2006) Clin Diabetes , vol.24 , Issue.3 , pp. 115-121
    • Briscoe, V.J.1    Davis, S.N.2
  • 23
    • 18144388647 scopus 로고    scopus 로고
    • Defining and reporting hypoglycemia in diabetes: A report from the American Diabetes Association Workgroup on Hypoglycemia
    • Workgroup on Hypoglycemia, American Diabetes Association
    • Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005; 28(5): 1245-1249.
    • (2005) Diabetes Care , vol.28 , Issue.5 , pp. 1245-1249
  • 24
    • 20444408424 scopus 로고    scopus 로고
    • Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: A population-based study
    • DARTS/MEMO Collaboration
    • Donnelly LA, Morris AD, Frier BM, et al; DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005; 22(6): 749-755.
    • (2005) Diabet Med , vol.22 , Issue.6 , pp. 749-755
    • Donnelly, L.A.1    Morris, A.D.2    Frier, B.M.3
  • 25
    • 33646678474 scopus 로고    scopus 로고
    • Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management
    • Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Saurio L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005; 29(3): 186-192.
    • (2005) Can J Diabetes , vol.29 , Issue.3 , pp. 186-192
    • Leiter, L.A.1    Yale, J.F.2    Chiasson, J.L.3    Harris, S.B.4    Kleinstiver, P.5    Saurio, L.6
  • 26
    • 84894563962 scopus 로고    scopus 로고
    • GAPP2™: Global survey finds three quarters of patients experience hypoglycaemia on insulin analogue causing dose irregularities and increased blood glucose monitoring
    • Tahrani A, Barnett A, Brod M, Rana M, Peyrot M. GAPP2™: Global survey finds three quarters of patients experience hypoglycaemia on insulin analogue causing dose irregularities and increased blood glucose monitoring. Diabetologia. 2012; 55 Suppl 1: S98-S99.
    • (2012) Diabetologia , vol.55 , Issue.SUPPL. 1
    • Tahrani, A.1    Barnett, A.2    Brod, M.3    Rana, M.4    Peyrot, M.5
  • 27
    • 80054749694 scopus 로고    scopus 로고
    • The incidence and costs of hypoglycemia in type 2 diabetes
    • Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care. 2011; 17(10): 673-680.
    • (2011) Am J Manag Care , vol.17 , Issue.10 , pp. 673-680
    • Quilliam, B.J.1    Simeone, J.C.2    Ozbay, A.B.3    Kogut, S.J.4
  • 28
    • 1042302782 scopus 로고    scopus 로고
    • Insulin administration
    • American Diabetes Association
    • American Diabetes Association. Insulin administration. Diabetes Care. 2004; 27(90001): 106S-107S.
    • (2004) Diabetes Care , vol.27
  • 29
    • 84862501914 scopus 로고    scopus 로고
    • Management of diabetes mellitus: Is the pump mightier than the pen?
    • Pickup JC. Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol. 2012; 8(7): 425-433.
    • (2012) Nat Rev Endocrinol , vol.8 , Issue.7 , pp. 425-433
    • Pickup, J.C.1
  • 30
    • 84874126435 scopus 로고    scopus 로고
    • Differential associations between depressive symptoms and glycaemic control in outpatients with diabetes
    • Bot M, Pouwer F, de Jonge P, Tack CJ, Geelhoed-Duijvestijn PH, Snoek FJ. Differential associations between depressive symptoms and glycaemic control in outpatients with diabetes. Diabet Med. 2013; 30(3): e115-e122.
    • (2013) Diabet Med , vol.30 , Issue.3
    • Bot, M.1    Pouwer, F.2    de Jonge, P.3    Tack, C.J.4    Geelhoed-Duijvestijn, P.H.5    Snoek, F.J.6
  • 31
    • 84867338418 scopus 로고    scopus 로고
    • Epidemiology of depression and diabetes: A systematic review
    • Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012; 142 Suppl: S8-S21.
    • (2012) J Affect Disord , vol.142 , Issue.SUPPL.
    • Roy, T.1    Lloyd, C.E.2
  • 32
    • 84878148848 scopus 로고    scopus 로고
    • Association of depression with increased risk of severe hypoglycemic episodes in patients with diabetes
    • Katon WJ, Young BA, Russo J, et al. Association of depression with increased risk of severe hypoglycemic episodes in patients with diabetes. Ann Fam Med. 2013; 11(3): 245-250.
    • (2013) Ann Fam Med , vol.11 , Issue.3 , pp. 245-250
    • Katon, W.J.1    Young, B.A.2    Russo, J.3
  • 33
    • 84879643475 scopus 로고    scopus 로고
    • Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus
    • Health ABC Study
    • Yaffe K, Falvey CM, Hamilton N, et al; Health ABC Study. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013; 173(14): 1300-1306.
    • (2013) JAMA Intern Med , vol.173 , Issue.14 , pp. 1300-1306
    • Yaffe, K.1    Falvey, C.M.2    Hamilton, N.3
  • 34
    • 77952766075 scopus 로고    scopus 로고
    • Determinants of severe hypoglycemia complicating type 2 diabetes: The Fremantle diabetes study
    • Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab. 2010; 95(5): 2240-2247.
    • (2010) J Clin Endocrinol Metab , vol.95 , Issue.5 , pp. 2240-2247
    • Davis, T.M.1    Brown, S.G.2    Jacobs, I.G.3    Bulsara, M.4    Bruce, D.G.5    Davis, W.A.6
  • 36
    • 26244459804 scopus 로고    scopus 로고
    • Pharmacokinetic and glucodynamic variability: Assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique
    • Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005; 48(10): 1988-1995.
    • (2005) Diabetologia , vol.48 , Issue.10 , pp. 1988-1995
    • Scholtz, H.E.1    Pretorius, S.G.2    Wessels, D.H.3    Becker, R.H.4
  • 37
    • 84899708585 scopus 로고    scopus 로고
    • Will the next generation of basal insulins offer clinical advantages?
    • Epub October 4
    • Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. Epub October 4, 2013.
    • (2013) Diabetes Obes Metab
    • Garber, A.J.1
  • 38
    • 84859921058 scopus 로고    scopus 로고
    • Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial
    • NN1250-3582 (BEGIN BB T2D) Trial Investigators
    • Garber AJ, King AB, Del Prato S, et al; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825): 1498-1507.
    • (2012) Lancet , vol.379 , Issue.9825 , pp. 1498-1507
    • Garber, A.J.1    King, A.B.2    Del Prato, S.3
  • 39
    • 84859896417 scopus 로고    scopus 로고
    • Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): A phase 3, randomised, open-label, treat-to-target non-inferiority trial
    • BEGIN Basal-Bolus Type 1 Trial Investigators
    • Heller S, Buse J, Fisher M, et al; BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825): 1489-1497.
    • (2012) Lancet , vol.379 , Issue.9825 , pp. 1489-1497
    • Heller, S.1    Buse, J.2    Fisher, M.3
  • 40
    • 84871937855 scopus 로고    scopus 로고
    • Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials
    • Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013; 15(2): 175-184.
    • (2013) Diabetes Obes Metab , vol.15 , Issue.2 , pp. 175-184
    • Ratner, R.E.1    Gough, S.C.2    Mathieu, C.3
  • 41
    • 84869842163 scopus 로고    scopus 로고
    • Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
    • NN1250-3579 (BEGIN Once Long) Trial Investigators
    • Zinman B, Philis-Tsimikas A, Cariou B, et al; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012; 35(12): 2464-2471.
    • (2012) Diabetes Care , vol.35 , Issue.12 , pp. 2464-2471
    • Zinman, B.1    Philis-Tsimikas, A.2    Cariou, B.3
  • 42
    • 84865972844 scopus 로고    scopus 로고
    • Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
    • Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012; 14(10): 944-950.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.10 , pp. 944-950
    • Heise, T.1    Nosek, L.2    Bøttcher, S.G.3    Hastrup, H.4    Haahr, H.5
  • 43
    • 84859883969 scopus 로고    scopus 로고
    • Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine
    • 37-LB, (abstract)
    • Heise T, Hövelmann U, Nosek L, Bøttcher S, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes. 2011; 60 Suppl 1A: 37-LB (abstract).
    • (2011) Diabetes , vol.60 , Issue.SUPPL. 1A
    • Heise, T.1    Hövelmann, U.2    Nosek, L.3    Bøttcher, S.4    Granhall, C.5    Haahr, H.6
  • 44
    • 84885871790 scopus 로고    scopus 로고
    • Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec
    • (abstract)
    • Heise T, Nosek L, Coester HV, et al. Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec. Diabetes 2012; 61 Suppl 1: A259 (abstract).
    • (2012) Diabetes , vol.61 , Issue.SUPPL. 1
    • Heise, T.1    Nosek, L.2    Coester, H.V.3
  • 45
    • 84864375931 scopus 로고    scopus 로고
    • Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
    • Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012; 14(9): 859-864.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.9 , pp. 859-864
    • Heise, T.1    Hermanski, L.2    Nosek, L.3    Feldman, A.4    Rasmussen, S.5    Haahr, H.6
  • 48
    • 84892925546 scopus 로고    scopus 로고
    • Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus
    • Korsatko S, Deller S, Mader JK, et al. Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus. Drugs Aging. 2013; 31(1): 47-53.
    • (2013) Drugs Aging , vol.31 , Issue.1 , pp. 47-53
    • Korsatko, S.1    Deller, S.2    Mader, J.K.3
  • 49
    • 84865855360 scopus 로고    scopus 로고
    • Ultra-long pharmacokinetic properties of insulin degludec in adults with type 1 diabetes is preserved in children and adolescents after single-dose administration
    • Danne T, Bieter T, Blaesig S, et al. Ultra-long pharmacokinetic properties of insulin degludec in adults with type 1 diabetes is preserved in children and adolescents after single-dose administration. Diabetologia. 2011; 54(Suppl 1): S425.
    • (2011) Diabetologia , vol.54 , Issue.SUPPL. 1
    • Danne, T.1    Bieter, T.2    Blaesig, S.3
  • 50
    • 11844250564 scopus 로고    scopus 로고
    • Insulin analogues
    • Hirsch IB. Insulin analogues. N Engl J Med. 2005; 352(2): 174-183.
    • (2005) N Engl J Med , vol.352 , Issue.2 , pp. 174-183
    • Hirsch, I.B.1
  • 51
    • 0037737732 scopus 로고    scopus 로고
    • Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review
    • DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003; 289(17): 2254-2264.
    • (2003) JAMA , vol.289 , Issue.17 , pp. 2254-2264
    • DeWitt, D.E.1    Hirsch, I.B.2
  • 52
    • 84892724602 scopus 로고    scopus 로고
    • Insulin stacking versus therapeutic accumulation: Understanding the differences
    • Heise T, Meneghini LF. Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract. 2013; 20(1): 75-83.
    • (2013) Endocr Pract , vol.20 , Issue.1 , pp. 75-83
    • Heise, T.1    Meneghini, L.F.2
  • 53
    • 84875444482 scopus 로고    scopus 로고
    • The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
    • NN1250-3668 (BEGIN FLEX) Trial Investigators
    • Meneghini L, Atkin SL, Gough SC, et al; NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013; 36(4): 858-864.
    • (2013) Diabetes Care , vol.36 , Issue.4 , pp. 858-864
    • Meneghini, L.1    Atkin, S.L.2    Gough, S.C.3
  • 54
    • 84874858316 scopus 로고    scopus 로고
    • Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension
    • NN1250-3770 (BEGIN: Flex T1) Trial Investigators
    • Mathieu C, Hollander P, Miranda-Palma B, et al; NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013; 98(3): 1154-1162.
    • (2013) J Clin Endocrinol Metab , vol.98 , Issue.3 , pp. 1154-1162
    • Mathieu, C.1    Hollander, P.2    Miranda-Palma, B.3
  • 55
    • 84888440169 scopus 로고    scopus 로고
    • Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial
    • Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013; 4(6): 605-612.
    • (2013) J Diabetes Investig , vol.4 , Issue.6 , pp. 605-612
    • Onishi, Y.1    Iwamoto, Y.2    Yoo, S.J.3    Clauson, P.4    Tamer, S.C.5    Park, S.6
  • 56
    • 84889648892 scopus 로고    scopus 로고
    • Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial
    • Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013; 36(9): 2536-2542.
    • (2013) Diabetes Care , vol.36 , Issue.9 , pp. 2536-2542
    • Gough, S.C.1    Bhargava, A.2    Jain, R.3    Mersebach, H.4    Rasmussen, S.5    Bergenstal, R.M.6
  • 57
    • 84899761571 scopus 로고    scopus 로고
    • Novo Nordisk, Accessed January 26, gov [website on the Internet], In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2008 [updated September 17, 2013]. Available from
    • Novo Nordisk. Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2008 [updated September 17, 2013]. Available from: http://clinicaltrials. gov/show/NCT00982644. NLM identifier: NCT00982644. Accessed January 26, 2014.
    • (2014) Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)
  • 58
    • 84899759954 scopus 로고    scopus 로고
    • Accessed January 26, Novo Nordisk, gov [website on the Internet], In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2009 [updated November 14, 2013]. Available from
    • Novo Nordisk. Comparison of NN1250 with insulin glargine plus insulin aspart with/without metformin and with/without pioglitazone in type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 14, 2013]. Available from: http://clinicaltrials. gov/ct2/show/NCT00972283. NLM identifier: NCT00972283. Accessed January 26, 2014.
    • (2014) Comparison of NN1250 with insulin glargine plus insulin aspart with/without metformin and with/without pioglitazone in type 2 diabetes (BEGIN™)
  • 59
    • 84899756910 scopus 로고    scopus 로고
    • Accessed January 26, gov [website on the Internet], Novo Nordisk, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2009 [updated November 28, 2013]. Available from
    • Novo Nordisk. Comparison of NN1250 plus insulin aspart with insulin glargine plus insulin aspart in type 1 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 28, 2013]. Available from: http://clinicaltrials. gov/show/NCT00982228. NLM identifier: NCT00982228. Accessed January 26, 2014.
    • (2014) Comparison of NN1250 plus insulin aspart with insulin glargine plus insulin aspart in type 1 diabetes (BEGIN™)
  • 60
    • 84899761571 scopus 로고    scopus 로고
    • Novo Nordisk, gov [website on the Internet], Accessed January 26, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2009 [updated November 26, 2013]. Available from
    • Novo Nordisk. Comparison of NN1250 with insulin glargine in type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated November 26, 2013]. Available from: http://clinicaltrials. gov/show/NCT01006291. NLM identifier: NCT01006291. Accessed January 26, 2014.
    • (2014) Comparison of NN1250 with insulin glargine in type 2 diabetes (BEGIN™)
  • 61
    • 84899721060 scopus 로고    scopus 로고
    • Novo Nordisk, gov [website on the Internet], Accessed January 26, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2010 [updated November 20, 2013]. Available from
    • Novo Nordisk. Comparison of NN1250 with insulin glargine in type 1 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 20, 2013]. Available from: http://clinicaltrials. gov/show/NCT01079234. NLM identifier: NCT01079234. Accessed January 26, 2014.
    • (2014) Comparison of NN1250 with insulin glargine in type 1 diabetes (BEGIN™)
  • 62
    • 84899761571 scopus 로고    scopus 로고
    • Novo Nordisk, gov [website on the Internet], Accessed January 26, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2010 [updated November 21, 2013]. Available from
    • Novo Nordisk. Comparison of NN1250 versus insulin glargine in subjects with type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 21, 2013]. Available from: http://clinicaltrials. gov/show/NCT01059799. NLM identifier: NCT01059799. Accessed January 26, 2014.
    • (2014) Comparison of NN1250 versus insulin glargine in subjects with type 2 diabetes (BEGIN™)
  • 63
    • 84899761571 scopus 로고    scopus 로고
    • Novo Nordisk, gov [website on the Internet], Accessed January 26, In: ClinicalTrials, Bethseda, MD: US National Library of Medicine; 2010 [updated November 26, 2013]. Available from
    • Novo Nordisk. Comparison of NN1250 with insulin glargine in subjects with type 2 diabetes (BEGIN™). In: ClinicalTrials. gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated November 26, 2013]. Available from: http://clinicaltrials. gov/show/NCT01068665. NLM identifier: NCT01068665. Accessed January 26, 2014.
    • (2014) Comparison of NN1250 with insulin glargine in subjects with type 2 diabetes (BEGIN™)
  • 64
    • 84899747668 scopus 로고    scopus 로고
    • Duration and impact of hypoglycemic events with insulin degludec and insulin glargine-a meta-analysis
    • Harris SB, Vora J, Christensen T, Kapur R, Brod M. Duration and impact of hypoglycemic events with insulin degludec and insulin glargine-a meta-analysis. Can J Diabetes. 2013; 37(Suppl 4): S54.
    • (2013) Can J Diabetes , vol.37 , Issue.SUPPL. 4
    • Harris, S.B.1    Vora, J.2    Christensen, T.3    Kapur, R.4    Brod, M.5
  • 65
    • 84899725387 scopus 로고    scopus 로고
    • Tresiba (degludec) [summary of product characteristics], Accessed January 26, Available from
    • Tresiba (degludec) [summary of product characteristics]. Bagsværd: Novo Nordisk; 2013. Available from: http://ec. europa. eu/health/documents/community-register/2013/20130121124987/anx_124987_en. pdf. Accessed January 26, 2014.
    • (2014) Bagsværd: Novo Nordisk; 2013
  • 66
    • 84884502135 scopus 로고    scopus 로고
    • Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: Results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials
    • NN1250-3724 (BEGIN: EASY AM), NN1250-3718 (BEGIN: EASY PM) Trial Investigators
    • Zinman B, DeVries JH, Bode B, et al; NN1250-3724 (BEGIN: EASY AM), NN1250-3718 (BEGIN: EASY PM) Trial Investigators. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol. 2013; 1(2): 123-131.
    • (2013) Lancet Diabetes Endocrinol , vol.1 , Issue.2 , pp. 123-131
    • Zinman, B.1    DeVries, J.H.2    Bode, B.3
  • 67
    • 84856591819 scopus 로고    scopus 로고
    • Improving safety of insulin administration: A pilot audit of hospital staff knowledge
    • Sharpe L. Improving safety of insulin administration: A pilot audit of hospital staff knowledge. J Diabetes Nurs. 2012; 16(1): 8-16.
    • (2012) J Diabetes Nurs , vol.16 , Issue.1 , pp. 8-16
    • Sharpe, L.1
  • 68
    • 84879814052 scopus 로고    scopus 로고
    • A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec
    • Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013; 33(7): 515-521.
    • (2013) Clin Drug Investig , vol.33 , Issue.7 , pp. 515-521
    • Korsatko, S.1    Deller, S.2    Koehler, G.3
  • 69
    • 3042823834 scopus 로고    scopus 로고
    • Hypoglycaemia in elderly patients with diabetes mellitus: Causes and strategies for prevention
    • Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004; 21(8): 511-530.
    • (2004) Drugs Aging , vol.21 , Issue.8 , pp. 511-530
    • Chelliah, A.1    Burge, M.R.2
  • 70
    • 0030852089 scopus 로고    scopus 로고
    • Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas
    • Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997; 157(15): 1681-1686.
    • (1997) Arch Intern Med , vol.157 , Issue.15 , pp. 1681-1686
    • Shorr, R.I.1    Ray, W.A.2    Daugherty, J.R.3    Griffin, M.R.4
  • 71
    • 84892924090 scopus 로고    scopus 로고
    • Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: A meta-analysis of phase IIIa trials
    • Sorli C, Warren M, Oyer D, Mersebach H, Johansen T, Gough SC. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials. Drugs Aging. 2013; 30(12): 1009-1018.
    • (2013) Drugs Aging , vol.30 , Issue.12 , pp. 1009-1018
    • Sorli, C.1    Warren, M.2    Oyer, D.3    Mersebach, H.4    Johansen, T.5    Gough, S.C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.